Rolex Forums - Rolex Watch Forum - View Single Post

Ichiran · 12 November 2023, 12:32 PM

Swiss Watch Magazine has a very good write-up of the OnlyWatch situation. It is great to know one of the companies concerned has started human clinical trial on the first boy in June 2023. Hope we are not too far away from a cure.

https://swisswatches-magazine.com/bl...ure-is-rising/

"Now, all eyes are on Only Watch, and it is up to them to do everything they can to show that the funds have been properly utilised. It is important to note that SQY Therapeutics has already started a human clinical trial. On 14 June 2023, the first of 12 boys with Duchenne muscular dystrophy received his first dose of the SQY51 compound at the Raymond Poincaré Hospital in Garches. The other eleven participants followed one after the other at intervals of at least one week. It is thus indisputably proven that funds were used to finance extensive research and development work. However, to dispel any doubts, Only Watch will need to return with leadership that can ensure the transparent continuation of the auction. To regain credibility, it will also be necessary for the Pettavinos to no longer be shareholders in SQY Therapeutics and for their shares to be sold to the parents’ associations (who initiated the foundation of the company)."

12 November 2023, 12:32 PM	#29
Ichiran 2024 Pledge Member Join Date: Jan 2018 Real Name: Michael Location: Dotonbori Watch: Mostly blue dials Posts: 7,671	Swiss Watch Magazine has a very good write-up of the OnlyWatch situation. It is great to know one of the companies concerned has started human clinical trial on the first boy in June 2023. Hope we are not too far away from a cure. https://swisswatches-magazine.com/bl...ure-is-rising/ "Now, all eyes are on Only Watch, and it is up to them to do everything they can to show that the funds have been properly utilised. It is important to note that SQY Therapeutics has already started a human clinical trial. On 14 June 2023, the first of 12 boys with Duchenne muscular dystrophy received his first dose of the SQY51 compound at the Raymond Poincaré Hospital in Garches. The other eleven participants followed one after the other at intervals of at least one week. It is thus indisputably proven that funds were used to finance extensive research and development work. However, to dispel any doubts, Only Watch will need to return with leadership that can ensure the transparent continuation of the auction. To regain credibility, it will also be necessary for the Pettavinos to no longer be shareholders in SQY Therapeutics and for their shares to be sold to the parents’ associations (who initiated the foundation of the company)."